


Supplemental Figure 1. MacSynergy II plots for antiviral combination effects between LDV with IFN- α and Ribavirin. Elevations in the Z-plane indicate areas of synergy whereas depressions indicate antagonism.



Supplemental Figure 2: MacSynergy II plots for antiviral combination effects between LDV and NS3/4A protease inhibitors GS-9451 and simeprevir (SMV), the NS5A inhibitor DCV, as well as non-nucleoside (GS-9669) and nucleoside (SOF) NS5B polymerase inhibitors. Elevations in the Z-plane indicate areas of synergy whereas depressions indicate antagonism.

Supplemental Table 1. HIV inhibitors do not affect LDV potency in GT 1a replicon cells

HIV Inhibitor Concentration	LDV EC ₅₀ (nM) ^a							
	EFV	EVG	TFV	DRV	FTC	ATV	RPV	RAL
15 µM	0.055 ± 0.029	0.046 ± 0.007	0.035 ± 0.002	0.085 ± 0.029	0.019 ± 0.002	0.007 ± 0.0004	0.009 ± 0.003	0.014 ± 0.005
1.5 µM	0.030 ± 0.008	0.04 ± 0.007	0.03 ± 0.007	0.046 ± 0.022	0.024 ± 0.007	0.015 ± 0.003	0.01 ± 0.001	0.019 ± 0.002
0.15 µM	0.032 ± 0.011	0.046 ± 0.018	0.029 ± 0.005	0.04 ± 0.013	0.02 ± 0.005	0.017 ± 0.001	0.015 ± 0.001	0.017 ± 0.003
0 µM	0.038 ± 0.013	0.09 ± 0.014	0.031 ± 0.007	0.04 ± 0.011	0.015 ± 0.002	0.017 ± 0.003	0.014 ± 0.004	0.018 ± 0.002

a No cytotoxicity observed for any of the concentrations tested

Supplemental Table 2. LDV does not affect HIV inhibitor potency in HIV infection assays

LDV (EC ₅₀)	EC ₅₀ (nM) ^a							
	EFV	EVG	TFV	DRV	FTC	ATV	RPV	RAL
20X	1.97 ± 0.05	3.27 ± 0.37	8137 ± 1142	7.35 ± 0.12	1262.9 ± 200.6	9.90 ± 0.82	0.13 ± 0.003	10.79 ± 0.69
5X	2.02 ± 0.16	3.42 ± 0.13	9819 ± 1490	6.79 ± 0.56	1173.9 ± 107.0	9.57 ± 0.47	0.14 ± 0.02	8.88 ± 1.38
1X	1.92 ± 0.12	3.11 ± 0.07	10220 ± 636	7.32 ± 0.28	1186.6 ± 169.2	10.30 ± 0.40	0.12 ± 0.007	9.45 ± 1.30
None	1.21 ± 0.15	1.70 ± 0.15	7246 ± 292	6.31 ± 0.23	614.7 ± 189.6	8.18 ± 0.16	0.07 ± 0.012	7.26 ± 1.88

a No cytotoxicity observed for any of the concentrations tested